机构地区:[1]河北省保定市第二中心医院检验科,072750 [2]河北省保定市第二中心医院消化内科,072750 [3]河北省保定市第二中心医院急诊科,072750 [4]河北省保定市第二中心医院放射科,072750
出 处:《临床外科杂志》2024年第9期937-941,共5页Journal of Clinical Surgery
基 金:保定市科技计划项目(2341ZF037)。
摘 要:目的 探析血清尿酸水平对原发性肝癌(PLC)病人肝切除术后肌少症发生的预测价值。方法 采用便利抽样法,前瞻性纳入2019年1月~2021年12月行肝切除术治疗的PLC病人161例,根据是否并发肌少症分为发生组和未发生组。比较两组病人临床资料、血清尿酸等血液生化检查结果,分析血清尿酸水平对PLC病人肝切除术后发生肌少症的预测价值和影响。结果本研究最终收录的158例行肝切除术治疗的PLC病人中,有34例术后发生肌少症,发生率为21.52%。发生组的血尿酸水平为(311.79±35.32)μmol/L,高于未发生组的(280.52±31.15)μmol/L,ALB水平为(31.59±5.73)g/L,低于未发生组的(35.63±5.13)g/L,术后辅助性肝动脉灌注化疗(HAIC)占38.24%,高于未发生组的20.16%,两组比较差异有统计学意义(P<0.05)。多元logistic回归分析结果显示,血清尿酸、ALB、术后辅助性肝动脉灌注化疗与PLC病人肝切除术后发生肌少症有关(OR=0.853、1.035、11.189,95%CI:0.770~0.945、1.018~1.052、3.533~35.433,P<0.05)。绘制受试者工作特征曲线(ROC)显示,血清尿酸预测PLC病人肝切除术后发生肌少症的曲线下面积(AUC)为0.754(95%CI:0.657~0.850)。绘制列线图发现,血清尿酸辅助其他主要临床指标构建的预测模型预测PLC病人肝切除术后肌少症发生的C-index为0.847(95%CI:0.782~0.913),提示模型一定预测价值;绘制决策曲线结果显示,阈值在0~1.00范围内,模型临床实际净受益率始终>0,最大净受益率为0.215,提示模型具有良好的临床应用价值。结论 PLC病人血清尿酸水平升高是其术后发生肌少症的危险因素,检测血清尿酸水平有助于辅助临床早期预测肌少症发生风险。Objective To explore the predictive value of serum uric acid levels for the occurrence of sarcopenia after hepatectomy in patients with primary liver cancer(PLC).Method A convenience sampling method was used to prospectively include 161 PLC patients who underwent liver resection surgery at Baoding NO.2 Central Hospital of Hebei Province from January 2019 to December 2021.They were divided into occurrence group and non occurrence group based on whether they had muscle deficiency.The clinical data,serum uric acid and other blood biochemical examination results were compared between the two groups,and the predictive value and influence of serum uric acid level on sarcopenia after hepatectomy in PLC patients were analyzed.Results Among the 158 PLC patients who underwent hepatectomy in the final inclusion of this study,34 patients developed postoperative sarcopenia,with an incidence rate of approximately 21.52%.The serum uric acid level(311.79±35.32)μmol/L in the occurrence group was higher than that in the non-occurrence group(280.52±31.15)μmol/L,the ALB level(31.59±5.73)g/L was lower than that in the non-occurrence group(35.63±5.13)g/L,and the proportion of postoperative adjuvant hepatic arterial infusion chemotherapy(HAIC)(38.24%)was higher than that in the non-occurrence group(20.16%),with statistical significant differences(P<0.05).Multiple Logistic regression analysis showed that serum uric acid、ALB、postoperative adjuvant HAIC were associated with sarcopenia after hepatectomy in PLC patients(OR=0.853,1.035,11.189,95%CI:0.770-0.945,1.018-1.052,3.533-35.433,P<0.05).The receiver operating characteristic curve(ROC)showed that the area under the curve(AUC)of serum uric acid in predicting sarcopenia after hepatectomy in PLC patients was 0.754(95%CI:0.657-0.850),which had certain predictive value.The nomogram showed that the C-index of the prediction model constructed by serum uric acid assisted other major clinical indicators to predict the occurrence of sarcopenia after hepatectomy in PLC patients was 0.847
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...